Ventricular Assist Devices as a Bridge to Cardiac Transplantation: The Ottawa Experience
: This article reports our experience with ventricular assist devices (VADs) as a bridge to cardiac transplan‐tation. From 1991 to 2003, a total of 42 patients received a Thoratec VAD (Thoratec Laboratories Corporation Inc., Pleasanton, CA, U.S.A.) (Group T) and 12 patients received...
Gespeichert in:
| Veröffentlicht in: | Artificial organs 2004-02, Vol.28 (2), p.136-141 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 141 |
|---|---|
| container_issue | 2 |
| container_start_page | 136 |
| container_title | Artificial organs |
| container_volume | 28 |
| creator | Haddad, Michel Hendry, Paul J. Masters, Roy G. Mesana, Thierry Haddad, Haissam Davies, Ross A. Mussivand, Tofy V. Struthers, Christine Keon, Wilbert J. |
| description | : This article reports our experience with ventricular assist devices (VADs) as a bridge to cardiac transplan‐tation. From 1991 to 2003, a total of 42 patients received a Thoratec VAD (Thoratec Laboratories Corporation Inc., Pleasanton, CA, U.S.A.) (Group T) and 12 patients received a Novacor VAD (WorldHeart Corporation, Ottawa, Canada) (Group N). Thirty Thoratec patients were transplanted compared to six in the Novacor group. Four more Novacor patients are still supported. Of the transplanted patients, 87% survived to hospital discharge in Group T and 67% in Group N. Infections affected 29% and 50% of Group T patients during support and post‐transplantation, respectively, compared to 25% and 0%, respectively, in Group N. Neurologic complications affected 33% of patients in each group during support. Reopening rates for bleeding during support were 45% and 42% in Groups T and N, respectively. There were no significant differences in outcomes between the two groups. Our study demonstrated the effectiveness of VADs in bridging mortally ill cardiac patients to successful heart transplantation. |
| doi_str_mv | 10.1111/j.1525-1594.2003.47331.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80153744</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17940537</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5011-b86914c51ad6d3a7ae9f828c42407ef414d85bd0cb27d7f84280d40f0b29254d3</originalsourceid><addsrcrecordid>eNqNkdFu0zAUhi3ExMrgFZCvuEs4Tuw44QKplNGhVas0lVFxYzn2CbikSWenW_f2uGu1XYJlyZbOd34ffSaEMkhZXB9WKROZSJioeJoB5CmXec7S3Qsyeiq8JCNgBSSi4MtT8jqEFQBIDsUrcsp4VbBKsBFZ3mA3eGe2rfZ0HIILA_2Cd85goDpu-tk7-wvp0NOJ9tZpQxded2HT6m7Qg-u7j3TxG-l8GPS9pue7DXqHncE35KTRbcC3x_OMfP96vphcJLP59NtkPEuMAMaSuiwqxo1g2hY211Jj1ZRZaXjGQWLDGbelqC2YOpNWNiXPSrAcGqizKhPc5mfk_SF34_vbLYZBrV0w2Mb5sN8GVQITueT8nyCTFYeIRrA8gMb3IXhs1Ma7tfYPioHa61crtbes9pbVXr961K92sfXd8Y1tvUb73Hj0HYFPB-Detfjw38FqPL9-vMaA5BAQPwp3TwHa_1GFzKVQP66marbM-PTy-kb9zP8CdPyiOw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17940537</pqid></control><display><type>article</type><title>Ventricular Assist Devices as a Bridge to Cardiac Transplantation: The Ottawa Experience</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Haddad, Michel ; Hendry, Paul J. ; Masters, Roy G. ; Mesana, Thierry ; Haddad, Haissam ; Davies, Ross A. ; Mussivand, Tofy V. ; Struthers, Christine ; Keon, Wilbert J.</creator><creatorcontrib>Haddad, Michel ; Hendry, Paul J. ; Masters, Roy G. ; Mesana, Thierry ; Haddad, Haissam ; Davies, Ross A. ; Mussivand, Tofy V. ; Struthers, Christine ; Keon, Wilbert J.</creatorcontrib><description>: This article reports our experience with ventricular assist devices (VADs) as a bridge to cardiac transplan‐tation. From 1991 to 2003, a total of 42 patients received a Thoratec VAD (Thoratec Laboratories Corporation Inc., Pleasanton, CA, U.S.A.) (Group T) and 12 patients received a Novacor VAD (WorldHeart Corporation, Ottawa, Canada) (Group N). Thirty Thoratec patients were transplanted compared to six in the Novacor group. Four more Novacor patients are still supported. Of the transplanted patients, 87% survived to hospital discharge in Group T and 67% in Group N. Infections affected 29% and 50% of Group T patients during support and post‐transplantation, respectively, compared to 25% and 0%, respectively, in Group N. Neurologic complications affected 33% of patients in each group during support. Reopening rates for bleeding during support were 45% and 42% in Groups T and N, respectively. There were no significant differences in outcomes between the two groups. Our study demonstrated the effectiveness of VADs in bridging mortally ill cardiac patients to successful heart transplantation.</description><identifier>ISSN: 0160-564X</identifier><identifier>EISSN: 1525-1594</identifier><identifier>DOI: 10.1111/j.1525-1594.2003.47331.x</identifier><identifier>PMID: 14961951</identifier><language>eng</language><publisher>Oxford, UK and Malden, USA: Blackwell Science Inc</publisher><subject>Adolescent ; Adult ; Biventricular assist device ; Canada ; Female ; Heart Failure - therapy ; Heart Transplantation ; Heart-Assist Devices ; Humans ; Infection - etiology ; Intra-Aortic Balloon Pumping ; Ischemic Attack, Transient - etiology ; Left ventricular assist device ; Male ; Middle Aged ; Novacor ; Outcomes ; Postoperative Complications ; Prospective Studies ; Reoperation ; Shock, Cardiogenic - therapy ; Stroke - etiology ; Survival Analysis ; Thoratec ; Treatment Outcome</subject><ispartof>Artificial organs, 2004-02, Vol.28 (2), p.136-141</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5011-b86914c51ad6d3a7ae9f828c42407ef414d85bd0cb27d7f84280d40f0b29254d3</citedby><cites>FETCH-LOGICAL-c5011-b86914c51ad6d3a7ae9f828c42407ef414d85bd0cb27d7f84280d40f0b29254d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1525-1594.2003.47331.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1525-1594.2003.47331.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14961951$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haddad, Michel</creatorcontrib><creatorcontrib>Hendry, Paul J.</creatorcontrib><creatorcontrib>Masters, Roy G.</creatorcontrib><creatorcontrib>Mesana, Thierry</creatorcontrib><creatorcontrib>Haddad, Haissam</creatorcontrib><creatorcontrib>Davies, Ross A.</creatorcontrib><creatorcontrib>Mussivand, Tofy V.</creatorcontrib><creatorcontrib>Struthers, Christine</creatorcontrib><creatorcontrib>Keon, Wilbert J.</creatorcontrib><title>Ventricular Assist Devices as a Bridge to Cardiac Transplantation: The Ottawa Experience</title><title>Artificial organs</title><addtitle>Artif Organs</addtitle><description>: This article reports our experience with ventricular assist devices (VADs) as a bridge to cardiac transplan‐tation. From 1991 to 2003, a total of 42 patients received a Thoratec VAD (Thoratec Laboratories Corporation Inc., Pleasanton, CA, U.S.A.) (Group T) and 12 patients received a Novacor VAD (WorldHeart Corporation, Ottawa, Canada) (Group N). Thirty Thoratec patients were transplanted compared to six in the Novacor group. Four more Novacor patients are still supported. Of the transplanted patients, 87% survived to hospital discharge in Group T and 67% in Group N. Infections affected 29% and 50% of Group T patients during support and post‐transplantation, respectively, compared to 25% and 0%, respectively, in Group N. Neurologic complications affected 33% of patients in each group during support. Reopening rates for bleeding during support were 45% and 42% in Groups T and N, respectively. There were no significant differences in outcomes between the two groups. Our study demonstrated the effectiveness of VADs in bridging mortally ill cardiac patients to successful heart transplantation.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Biventricular assist device</subject><subject>Canada</subject><subject>Female</subject><subject>Heart Failure - therapy</subject><subject>Heart Transplantation</subject><subject>Heart-Assist Devices</subject><subject>Humans</subject><subject>Infection - etiology</subject><subject>Intra-Aortic Balloon Pumping</subject><subject>Ischemic Attack, Transient - etiology</subject><subject>Left ventricular assist device</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Novacor</subject><subject>Outcomes</subject><subject>Postoperative Complications</subject><subject>Prospective Studies</subject><subject>Reoperation</subject><subject>Shock, Cardiogenic - therapy</subject><subject>Stroke - etiology</subject><subject>Survival Analysis</subject><subject>Thoratec</subject><subject>Treatment Outcome</subject><issn>0160-564X</issn><issn>1525-1594</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkdFu0zAUhi3ExMrgFZCvuEs4Tuw44QKplNGhVas0lVFxYzn2CbikSWenW_f2uGu1XYJlyZbOd34ffSaEMkhZXB9WKROZSJioeJoB5CmXec7S3Qsyeiq8JCNgBSSi4MtT8jqEFQBIDsUrcsp4VbBKsBFZ3mA3eGe2rfZ0HIILA_2Cd85goDpu-tk7-wvp0NOJ9tZpQxded2HT6m7Qg-u7j3TxG-l8GPS9pue7DXqHncE35KTRbcC3x_OMfP96vphcJLP59NtkPEuMAMaSuiwqxo1g2hY211Jj1ZRZaXjGQWLDGbelqC2YOpNWNiXPSrAcGqizKhPc5mfk_SF34_vbLYZBrV0w2Mb5sN8GVQITueT8nyCTFYeIRrA8gMb3IXhs1Ma7tfYPioHa61crtbes9pbVXr961K92sfXd8Y1tvUb73Hj0HYFPB-Detfjw38FqPL9-vMaA5BAQPwp3TwHa_1GFzKVQP66marbM-PTy-kb9zP8CdPyiOw</recordid><startdate>200402</startdate><enddate>200402</enddate><creator>Haddad, Michel</creator><creator>Hendry, Paul J.</creator><creator>Masters, Roy G.</creator><creator>Mesana, Thierry</creator><creator>Haddad, Haissam</creator><creator>Davies, Ross A.</creator><creator>Mussivand, Tofy V.</creator><creator>Struthers, Christine</creator><creator>Keon, Wilbert J.</creator><general>Blackwell Science Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>200402</creationdate><title>Ventricular Assist Devices as a Bridge to Cardiac Transplantation: The Ottawa Experience</title><author>Haddad, Michel ; Hendry, Paul J. ; Masters, Roy G. ; Mesana, Thierry ; Haddad, Haissam ; Davies, Ross A. ; Mussivand, Tofy V. ; Struthers, Christine ; Keon, Wilbert J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5011-b86914c51ad6d3a7ae9f828c42407ef414d85bd0cb27d7f84280d40f0b29254d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Biventricular assist device</topic><topic>Canada</topic><topic>Female</topic><topic>Heart Failure - therapy</topic><topic>Heart Transplantation</topic><topic>Heart-Assist Devices</topic><topic>Humans</topic><topic>Infection - etiology</topic><topic>Intra-Aortic Balloon Pumping</topic><topic>Ischemic Attack, Transient - etiology</topic><topic>Left ventricular assist device</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Novacor</topic><topic>Outcomes</topic><topic>Postoperative Complications</topic><topic>Prospective Studies</topic><topic>Reoperation</topic><topic>Shock, Cardiogenic - therapy</topic><topic>Stroke - etiology</topic><topic>Survival Analysis</topic><topic>Thoratec</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haddad, Michel</creatorcontrib><creatorcontrib>Hendry, Paul J.</creatorcontrib><creatorcontrib>Masters, Roy G.</creatorcontrib><creatorcontrib>Mesana, Thierry</creatorcontrib><creatorcontrib>Haddad, Haissam</creatorcontrib><creatorcontrib>Davies, Ross A.</creatorcontrib><creatorcontrib>Mussivand, Tofy V.</creatorcontrib><creatorcontrib>Struthers, Christine</creatorcontrib><creatorcontrib>Keon, Wilbert J.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Artificial organs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haddad, Michel</au><au>Hendry, Paul J.</au><au>Masters, Roy G.</au><au>Mesana, Thierry</au><au>Haddad, Haissam</au><au>Davies, Ross A.</au><au>Mussivand, Tofy V.</au><au>Struthers, Christine</au><au>Keon, Wilbert J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ventricular Assist Devices as a Bridge to Cardiac Transplantation: The Ottawa Experience</atitle><jtitle>Artificial organs</jtitle><addtitle>Artif Organs</addtitle><date>2004-02</date><risdate>2004</risdate><volume>28</volume><issue>2</issue><spage>136</spage><epage>141</epage><pages>136-141</pages><issn>0160-564X</issn><eissn>1525-1594</eissn><abstract>: This article reports our experience with ventricular assist devices (VADs) as a bridge to cardiac transplan‐tation. From 1991 to 2003, a total of 42 patients received a Thoratec VAD (Thoratec Laboratories Corporation Inc., Pleasanton, CA, U.S.A.) (Group T) and 12 patients received a Novacor VAD (WorldHeart Corporation, Ottawa, Canada) (Group N). Thirty Thoratec patients were transplanted compared to six in the Novacor group. Four more Novacor patients are still supported. Of the transplanted patients, 87% survived to hospital discharge in Group T and 67% in Group N. Infections affected 29% and 50% of Group T patients during support and post‐transplantation, respectively, compared to 25% and 0%, respectively, in Group N. Neurologic complications affected 33% of patients in each group during support. Reopening rates for bleeding during support were 45% and 42% in Groups T and N, respectively. There were no significant differences in outcomes between the two groups. Our study demonstrated the effectiveness of VADs in bridging mortally ill cardiac patients to successful heart transplantation.</abstract><cop>Oxford, UK and Malden, USA</cop><pub>Blackwell Science Inc</pub><pmid>14961951</pmid><doi>10.1111/j.1525-1594.2003.47331.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0160-564X |
| ispartof | Artificial organs, 2004-02, Vol.28 (2), p.136-141 |
| issn | 0160-564X 1525-1594 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80153744 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescent Adult Biventricular assist device Canada Female Heart Failure - therapy Heart Transplantation Heart-Assist Devices Humans Infection - etiology Intra-Aortic Balloon Pumping Ischemic Attack, Transient - etiology Left ventricular assist device Male Middle Aged Novacor Outcomes Postoperative Complications Prospective Studies Reoperation Shock, Cardiogenic - therapy Stroke - etiology Survival Analysis Thoratec Treatment Outcome |
| title | Ventricular Assist Devices as a Bridge to Cardiac Transplantation: The Ottawa Experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T21%3A49%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ventricular%20Assist%20Devices%20as%20a%20Bridge%20to%20Cardiac%20Transplantation:%20The%20Ottawa%20Experience&rft.jtitle=Artificial%20organs&rft.au=Haddad,%20Michel&rft.date=2004-02&rft.volume=28&rft.issue=2&rft.spage=136&rft.epage=141&rft.pages=136-141&rft.issn=0160-564X&rft.eissn=1525-1594&rft_id=info:doi/10.1111/j.1525-1594.2003.47331.x&rft_dat=%3Cproquest_cross%3E17940537%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17940537&rft_id=info:pmid/14961951&rfr_iscdi=true |